Co announces that it has signed a non-exclusive STAR(TM) research license agreement for the production of monoclonal antibodies with Abbott (ABT). Under the agreement, Abbott would evaluate Crucell's STAR(TM) technology for generating cell lines for manufacture of biopharmaceuticals. Financial details were not disclosed.










